Switching from branded to generic inhaled medications: Potential impact on asthma and COPD

Expert Opinion on Drug Delivery

Volumn 10, Issue 12, 2013, Pages 1597-1602

  Lavorini, Federico ^a   Ninane, Vincent ^b   Haughney, John ^c   Bjermer, Leif ^d   Molimard, Mathieu ^e   Dekhuijzen, Richard P N ^f  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; Asthma; Compliance; COPD; Generics; Inhalers; Switching

Indexed keywords

BUDESONIDE; EXCIPIENT; GENERIC DRUG; SALBUTAMOL; STEROID;

ASTHMA; BIOEQUIVALENCE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRY POWDER INHALER; EUROPE; FINLAND; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FRANCE; HEALTH CARE PERSONNEL; HUMAN; LUNG; METERED DOSE INHALER; MORBIDITY; MORTALITY; NEBULIZER; NEW ZEALAND; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; STRESS; SWEDEN; TREATMENT REFUSAL; UNCERTAINTY; UNITED KINGDOM; DRUG LEGISLATION; DRUG SUBSTITUTION; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

ADMINISTRATION, INHALATION; ASTHMA; DRUG SUBSTITUTION; DRUGS, GENERIC; EUROPE; HUMANS; LEGISLATION, DRUG; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84889043980     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.852182     Document Type: Review

References (33)

1. Available from: http://www.edctp.org/ fileadmin/documents/ethics/ Directive-200183EC-of-the-european -parliament.pdf [Accessed 1 May 2013]
2. Garca-Arieta A, Gordon J. Bioequivalence requirements in the European Union: critical discussion. AAPS J 2012;14:738-48
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease. In: (CHMP) CfMPfHU editor. London: 2009
4. US Food and Drug Administration. US FDA. Drug-development approval process. Scientific and regulatory considerations for bioequivalence (BE) of Dry Powder Inhalers (DPIs); 2011
5. Daley-Yates P, Parkins D. Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv 2011;8:1297-308
6. GINA. GINA report, global strategy for asthma management and prevention, December 2011 update. Available from: http://www.ginasthma.org/
7. GOLD. Global strategy for diagnosis, management, and prevention of COPD (2011 update): global initiative for chronic obstructive lung disease. 2011. Available from: http://www. goldcopd.org/
8. Price D, Summers M, Zanen P. Could interchangeable use of dry powder inhalers affect patients? Int J Clin Pract 2005;59(Suppl 149):3-6 (Pubitemid 44890360)
9. Evans C, Cipolla D, Chesworth T, et al. Equivalence considerations for orally inhaled products for local action-ISAM/ IPAC-RS European Workshop report. J Aerosol Med Pulm Drug Deliv 2012;25:117-39
10. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/ hybrid inhalation products intended for treatment of asthma and COPD. J Aerosol Med Pulm Drug Deliv 2012;25:243-7
11. Adams WP, Ahrens RC, Chen ML, et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv 2010;23:1-29
12. Ousterhout M. Generic inhaled corticosteroids: Current status and what to expect next. Formulary 2011
13. CBIP. Prescription en DCI. Propositions pour l'application pratique dans la pratique medicale et pharmaceutique et dans le dossier medical electronique; 2010
14. Lung Alliance Network. Correct use of inhaled medication asthma and COPD. Amersfoort: 2011
15. Stenson J. Report questions generic antidepressant. MASNB 2007
16. Liow K, Barkley G, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for treatment of epilepsy. Neurology 2007;68:1249-50 (Pubitemid 46625968)
17. AACE TES ATA. Joint position statement on the use and interchangeability of thyroxine products. 2004.Available from: Thyroid.org AACE, TES and ATA [Cited 2007]
18. Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J 2012;21:208-13
19. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-54 (Pubitemid 37169635)
20. Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their consent? Prim Care Respir J 2010;19:131-9
21. PHARMAC. New Zealand pharmaceutical schedule update effective. PHARMAC; Wellington: 2005
22. Dockhorn D, Vanden Burgt J, Ekholm BP, et al. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995;96:50-6
23. Gillies J, Brown J, Byrnes C, et al. PHARMAC and ventolin in New Zealand. NZ Med 2005;120:1220
24. Reti S. Ventolin to Salamol - a crossover study in New Zealand. NZ Med 2006;119:1-7
25. Chang C, Cooray M, Mills G, Hancox R. Is Salamol less effective than Ventolin? A randomized, blinded, crossover, study in New Zealand. NZ Med 2007;120:1267
26. Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998;12:1340-5 (Pubitemid 29011426)
27. Thomas M, Price D, Chrystyn H, et al. Inhale corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009;9:1
28. Lavorini F, Magnan A, Dubus J, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102:593-604
29. Lavorini F, Levy M, Dekhuijzen P, Crompton G. Inhaler choice and inhalation technique: key factors for asthma control. Prim Care Respir J 2009;18:241-2
30. Price D. Do healthcare professionals think that dry powder inhalers can be used interchangeably? Int J Clin Pract Suppl 2005;149:26-9 (Pubitemid 44890364)
31. Booker R. Do patients think that dry powder inhalers can be used interchangeably? Int J Clin Pract 2005;59(Suppl 149):30-2 (Pubitemid 44890365)
32. Williams A, Chrystyn H. Survey of pharmacists' attitude towards interchangeable use of dry powder inhaler. Pharm World Sci 2007;29:221-7 (Pubitemid 46872985)
33. Available from: www.longalliantie.nl/ images/library/pdf/ Definitief%20rapport% 20Goed%20gebruik%20Inhalatiemedicatie %20astma%20en%20COPD%20december %202011%20Max.pdf